Literature DB >> 7752148

The structure of aggrecan and its turnover in cartilage.

T E Hardingham1, A J Fosang.   

Abstract

Aggrecan is the major proteoglycan in cartilage. It has a multidomain structure with 3 globular and 2 extended segments. It forms large aggregates by binding to hyaluronan via the G1 domain, and link protein stabilizes the aggrecan-hyaluronan bond. The extended interglobular domain joining G1 and G2 domains is the main site of proteolytic attack in aggrecan turnover. One site of cleavage is reported to predominate, but the enzyme responsible for this cleavage has not been identified. A metalloproteinase, neutrophil collagenase, has been shown to cleave at this "aggrecanase" site in vitro; however, it has yet to be shown if metalloproteinases are responsible for this activity in cartilage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752148

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  12 in total

1.  An aggrecan-degrading activity associated with chondrocyte membranes.

Authors:  C J Billington; I M Clark; T E Cawston
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

Review 2.  Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes.

Authors:  P J Verschure; C J Van Noorden; J Van Marle; W B Van den Berg
Journal:  Histochem J       Date:  1996-12

3.  Gel structure has an impact on pericellular and extracellular matrix deposition, which subsequently alters metabolic activities in chondrocyte-laden PEG hydrogels.

Authors:  G D Nicodemus; S C Skaalure; S J Bryant
Journal:  Acta Biomater       Date:  2010-09-08       Impact factor: 8.947

4.  Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1alpha.

Authors:  W Hui; A D Rowan; T Cawston
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

5.  Characterization of proteoglycan production and processing by chondrocytes and BMSCs in tissue engineered constructs.

Authors:  J T Connelly; C G Wilson; M E Levenston
Journal:  Osteoarthritis Cartilage       Date:  2008-02-21       Impact factor: 6.576

6.  Chondrocytes and meniscal fibrochondrocytes differentially process aggrecan during de novo extracellular matrix assembly.

Authors:  Christopher G Wilson; James F Nishimuta; Marc E Levenston
Journal:  Tissue Eng Part A       Date:  2009-07       Impact factor: 3.845

7.  Stem Cell-Based Tissue-Engineered Laryngeal Replacement.

Authors:  Tahera Ansari; Peggy Lange; Aaron Southgate; Karin Greco; Carla Carvalho; Leanne Partington; Anthony Bullock; Sheila MacNeil; Mark W Lowdell; Paul D Sibbons; Martin A Birchall
Journal:  Stem Cells Transl Med       Date:  2016-09-09       Impact factor: 6.940

Review 8.  Tissue engineering: chondrocytes and cartilage.

Authors:  Tim Hardingham; Simon Tew; Alan Murdoch
Journal:  Arthritis Res       Date:  2002-05-09

9.  Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

Authors:  Jean C Rousseau; Eren U Sumer; Gert Hein; Bodil C Sondergaard; Suzi H Madsen; Christian Pedersen; Thomas Neumann; Andreas Mueller; Per Qvist; Pierre Delmas; Morten A Karsdal
Journal:  BMC Musculoskelet Disord       Date:  2008-05-28       Impact factor: 2.362

Review 10.  Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis: Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity.

Authors:  Anthony J Hayes; James Melrose
Journal:  Biomolecules       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.